Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Anti-leukemic potency of piggyBac-mediated CD19-specific T cells against refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.

Cytotherapy - 1 Sept 2014

Saito Shoji, Nakazawa Yozo, Sueki Akane, Matsuda Kazuyuki, Tanaka Miyuki, Yanagisawa Ryu, Maeda Yasuhiro, Sato Yuko, Okabe Seiichi, Inukai Takeshi, Sugita Kanji, Wilson Matthew H, Rooney Cliona M, Koike Kenichi

Abstract excerpt

BACKGROUND AIMS: To develop a treatment option for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph(+)ALL) resistant to tyrosine kinase inhibitors (TKIs), we evaluated the anti-leukemic activity of T cells non-virally engineered to express a CD19-specific chimeric antigen receptor (CAR). METHODS: A CD19.CAR gene was delivered into mononuclear cells from 10 mL of blood of healthy donors through...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, CD19
Share to Cancer Vaccines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Culture Media, Serum-Free

Share to Cytotoxicity, Immunologic

Share to Immunotherapy, Adoptive

Share to Interleukin-15

Share to Interleukin-2

Share to TNF-Related Apoptosis-Inducing Ligand

Source

Open in PubMed Open full text

Identifiers

PMID: 25108652
DOI: 10.1016/j.jcyt.2014.05.022
PMCID: PMC4948190

Genes

CD19
CCR7
CD28
CD4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Anti-leukemic potency of piggyBac-mediated CD19-specific T cells against refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.PMID 25108652Read ↗

PiggyBac Transposon-Mediated CD19 Chimeric Antigen Receptor-T Cells Derived From CD45RA-Positive Peripheral Blood Mononuclear Cells Possess Potent and Sustained Antileukemic Function.Semantic proximity Read ↗

CAR therapy: the CD19 paradigmSemantic proximity Read ↗

<i>piggyBac</i> Transposon/Transposase System to Generate CD19-Specific T Cells for the Treatment of B-Lineage MalignanciesSemantic proximity Read ↗

Bispecific T-cells Expressing Polyclonal Repertoire of Endogenous γδ T-cell Receptors and Introduced CD19-specific Chimeric Antigen ReceptorSemantic proximity Read ↗

Phytohemagglutinin-Activated CAR-T Cells: Prolonged Persistence and Enhanced Anti-Tumor Response in CD19-Specific Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Tandem CD19/CD22 CAR-T cells conquer high-risk cytogenetics and acquire complete remission in r/r B-ALL patientsSemantic proximity Read ↗

In Vivo Generation of CAR T Cells Selectively in Human CD4+ LymphocytesSemantic proximity Read ↗

Donor-derived CARCIK-CD19 cells engineered with Sleeping Beauty transposon in acute lymphoblastic leukemia relapsed after allogeneic transplantationSemantic proximity Read ↗

Optimization of the PiggyBac Transposon System for the Sustained Genetic Modification of Human T LymphocytesSemantic proximity Read ↗

Redirecting Specificity of T-Cell Populations For CD19 Using the <i>Sleeping Beauty</i> SystemSemantic proximity Read ↗

Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cellsSemantic proximity Read ↗

A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALLSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.